

POSTER PRESENTATION

Open Access

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI

Maiko Matsushita^{1*}, Koji Ozawa¹, Saori Kanchi¹, Akane Uchiumi¹, Takuma Suzuki², Daiju Ichikawa¹, Eri Matsuki³, Masatoshi Sakurai³, Daiki Karigane³, Hidenori Kasahara³, Hideaki Nakajima³, Shinichiro Okamoto³, Yutaka Hattori¹

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Purpose

Tyrosine kinase inhibitors (TKIs) have improved overall survival of patients with chronic myeloid leukemia (CML). Moreover, it has been reported that some of the patients achieve treatment-free remission (TFR) after cessation of TKIs, even though leukemic stem cells (LSC) of CML are considered to be resistant to TKIs. Therefore, these findings suggest that remaining LSCs could be eradicated by immune system after withdrawal of TKIs. In order to clarify the role of anti-LSC immunity in achieving TFR, we tried to detect cytotoxic T cells against one of the LSC antigens, KU-MEL9 in CML patients.

Methods

Fresh blood samples were obtained from 16 CML patients who stopped imatinib after maintained complete molecular response (CMR) for more than two years at 0,3, and 6 months after cessation of imatinib. Mononuclear cells were stimulated with LSC antigen, KU-MEL9-derived nanomer peptide twice *in vitro*, then stained with anti-KU-MEL9-specific dextramer and analyzed by flow cytometry. Immunophenotype of lymphocytes was also determined by flow cytometry.

Results

We detected KU-MEL9-specific CTLs in 3 of 16 patients (Table 1). All of these patients remained in CMR at least 12 months after cessation of imatinib. On the other hand, none of 4 patients who showed molecular relapse presented with KU-MEL9-specific CTLs. The relapse rate of patients without KU-MEL9-CTLs was 31.3%, as compared to 0 % in KU-MEL9-CTL-positive patients. Percentage of

Table 1

Patients	0m	3m	6m	Clinical course
1	-	-	-	Molecular relapse
2	-	-	-	CMR
3	-	-	+	CMR
4	-	-	-	CMR
5	-	-	-	CMR
6	-	+	-	CMR
7	-	-	-	CMR
8	-	-	-	Molecular relapse
9	-	-	-	CMR
10	-	-	-	CMR
11	-	-	-	Molecular relapse
12	-	-	-	Molecular relapse
13	-	-	-	CMR
14	+	-	-	CMR
15	-	-	-	CMR
16	-	-	-	CMR

CD4⁺ CD25⁺ cells was higher in patients who experienced loss of CMR.

Conclusion

We found LSC antigen-specific T cells only in patients who achieved TFR. Although the patient size is small, these data suggest that anti-LSC CTLs may play a role in eradicating remaining LSCs after imatinib treatment and LSC antigen-specific immunotherapy could be useful to increase TFR rate.

Consent

Written informed consent was obtained from the patients for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

¹Faculty of Pharmacy, Keio University, Tokyo, Japan
Full list of author information is available at the end of the article

Authors' details

¹Faculty of Pharmacy, Keio University, Tokyo, Japan. ²Division of Pharmacy, National Cancer Center Hospital, Tokyo, Japan. ³Division of Hematology, Keio University, Tokyo, Japan.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P260

Cite this article as: Matsushita *et al.*: Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P260.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

